| 摘要 |
Disclosed herein are compounds of formula (I), wherein R<sp>1</sp> is hydroxy or NHSO<sb>2</sb>R<sp>1A</sp> wherein R<sp>1A</sp> is (C<sb>1-8</sb>)alkyl, (C<sb>3-7</sb>)cycloalkyl or {(C<sb>1-6</sb>)alkyl-(C<sb>3-7</sb>)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O-(C<sb>1-6</sb>)alkyl, amido, amino or phenyl, or R<sp>1A</sp> is C<sb>6</sb> or C<sb>10</sb> aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C<sb>1-6</sb>)alkyl, O-(C<sb>1 6</sb>)alkyl, amido, amino or phenyl; R<sp>2</sp> is (C<sb>4-6</sb>)cycloalkyl; R<sp>3</sp> is t-btuyl or (C<sb>5-6</sb>)cycloalkyl and R<sp>4</sp> is (C<sb>4-6</sb>)cycloalkyl; or a pharmaceutically acceptable salt thereof. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of Hepatitis C.
|
| 申请人 |
BOEHRINGER INGELHEIM INTERNATIONAL GMBH;LLINAS-BRUNET, MONTSE;GORYS, VIDA, J. |
发明人 |
LLINAS-BRUNET, MONTSE;GORYS, VIDA, J. |
